Old Web
English
Sign In
Acemap
>
authorDetail
>
Peter E. Haroldsen
Peter E. Haroldsen
BioMarin Pharmaceutical
Medicine
Metabolite
Pharmacology
Amifampridine
Pharmacokinetics
5
Papers
30
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Reveglucosidase alfa (BMN 701), an IGF 2 Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease
2017
Journal of Pharmacology and Experimental Therapeutics
Jeff Peng
Jill Dalton
Mark T. Butt
Kristin Tracy
Derek Kennedy
Peter E. Haroldsen
Rhea Cahayag
Stephen Zoog
Charles A. O'Neill
Laurie Tsuruda
Show All
Source
Cite
Save
Citations (4)
Acetylator Status Impacts Amifampridine Phosphate (Firdapse™) Pharmacokinetics and Exposure to a Greater Extent Than Renal Function
2017
Clinical Therapeutics
Peter E. Haroldsen
Zlatko Sisic
Joe Datt
Donald G. Musson
Gary Ingenito
Show All
Source
Cite
Save
Citations (6)
Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate
2015
Pharmacology Research & Perspectives
Peter E. Haroldsen
Marvin R. Garovoy
Donald G. Musson
Huiyu Zhou
Laurie Tsuruda
Boyd Hanson
Charles A. O'Neill
Show All
Source
Cite
Save
Citations (13)
Genetic Regulation of Amifampridine Phosphate (Firdapse(R)) Metabolism Produces Significant Differences in Pharmacokinetics and Side Effects (P04.095)
2012
Neurology
Peter E. Haroldsen
Marvin R. Garovoy
Show All
Source
Cite
Save
Citations (0)
1